All In Biotech

Drug Trial Radar · NCT04643418

Phase 1/2a Study of MPB-1734 in Patients With Advanced Solid Tumors

Phase 1/2a Dose-ranging, Safety, Pharmacokinetics, and Preliminary Efficacy Study of MPB-1734 in Patients With Advanced Solid Tumors in Part 1 and With Selected Solid Tumors in Part 2

Last checked: Nov 19, 2026Latest source record: Nov 3, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

81

Planned (sponsor's estimate)

Start

Mar 8, 2022

Primary completion

Mar 31, 2025

Study completion Dec 2025

Sponsor

Lead sponsor
MegaPro Biomedical Co. Ltd.Industry
Sponsor type
Industry
First posted
Nov 25, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a first-in-human (FIH), multicenter, open-label, uncontrolled, Phase 1/2a study with dose escalation in patients with advanced solid tumors (Part 1) and cohorts of up to 15 patients per selected indication (Part 2). The solid tumor types in Part 2 will be decided by the sponsor prior to the start of Part 2, but not be solely based on the efficacy results in Part 1.

Conditions

  • Solid Tumor, Unspecified, Adult

Interventions

  • MPB-1734Drug

    Administered once daily in a 21-day cycle

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Evaluation the the maximum tolerated dose(MTD) by safety dataTime frame: Through the end of the first cycle (Days 1-21).

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Taipei Veterans General Hospital

    Taipei, Taiwan · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.